Recent studies have shown that mTOR inhibition can increase CD133+ subsets by abrogating differentiation of CD133+ cells and enhancing apoptosis of CD133− subpopulations in liver cancer cell lines [40]. The gene discussed is PROM1; the disease is liver cancer.